Molecular Staging of Lung and Esophageal Cancer  

Oleh:

Lau, Christine L. ; Moore, Mary-Beth H. ; Brooks, Kelly R. ; D’Amico, Thomas A. ; Harpole, David H., (Jr.)

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The Surgical Clinics of North America (Keterangan: ada di ClinicalKey) vol. 82 no. 3 (Jun. 2002), page 497.

Isi artikel

The most important predictor of survival in both non small-cell lung cancer (NSCLC) and esophageal cancer is the TNM stage at diagnosis, with the best chance for cure remaining complete surgical resection. While both NSCLC and esophageal cancer in advanced stages carry a very poor prognosis, patients with earlier staged tumors may have favorable outcomes when treated aggressively. An understanding of tumor virulence on a molecular level may identify subsets of early stage patients with poorer prognosis. Additionally, markers capable of identifying patients with ad-vanced or metastatic disease would prevent unnecessary surgical procedures in this group. If a definitive set of tumor markers that document early recurrence could be identified, earlier intervention (radiation therapy or re-resection for a local recurrence, chemotherapy or a novel therapy for a distant recurrence) may increase the overall survival rate.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali